pharmaceutical pricing strategy

9.10.2013 Market Access

Product Pricing in Emerging Markets

By Yanis Saradjian, Director of Consulting In today’s global market, life science companies worldwide face challenges such as increased austerity measures, unfamiliar emerging markets payers and governments, greater emphasis on health economics...
 

3.25.2013 Market Access

Pricing Troubles in India: Compulsory Licensing on the Subcontinent

Fresh news out of India this week is likely to add to pharmaceutical companies' concerns about pricing and sales in emerging markets.  Despite indications in February that compulsory licensing may be coming to an end, on March 18, BDR Pharmaceuticals applied for...
 

3.4.2013 Market Access

Global Pressures = Pricing Challenges

Over the past few years, political, social and economic upheavals worldwide have thrust change on the life sciences landscape — and forced pricing teams to work overtime.  Today, these teams must deal with a series of events and trends that each have some effect...
 

2.5.2013 Market Access

I want THAT price: Understanding the Rationale Behind International Price Referencing

Growing up, siblings have an unspoken rule that  if one received something or was allowed to do something that another wasn’t, instantly, life became “unfair” for the other party.  The smaller the age differential between the siblings, the more unfair the...
 

12.10.2012 Brand Management

If Pricing Goes Wrong, the Whole Launch Goes Wrong

As the year comes to a close, Cutting Edge Information is taking a look at the best and worst brand launches in the US over the past year. The line between a massively successful launch and a potentially disastrous one is razor thin. With that a mind, we've put...
 

11.28.2012 Health Economics and Outcomes Research (HEOR)

HEOR Valuable from Lab to Launch

In this harsh reimbursement environment, payers are looking beyond a drug’s efficacy and to its cost-effectiveness when approving drugs for their formularies.  To adapt to new payer demands, pharma companies are incorporating health economics and outcomes research...
 

8.1.2012 Account Strategy for Government

Understand Payer Groups’ Needs to Secure Reimbursement

Before US managed markets teams approach payers, they need to understand the different payer groups. All groups — Medicare and Medicaid, insurance companies, specialty pharmacies, hospitals, etc. — share the same fundamental function: to sift through the many...
 

7.26.2012 Managed Care Liaison / HOL

Health Outcomes Liaisons Are an Important Communication Channel with Payers

As payer relationships become more important than ever, many companies are working hard to build and support teams that can communicate pharmacoeconomic benefits to payers. The members on these teams, often called outcomes liaisons or health outcomes liaisons (HOLs),...
 

6.5.2012 Market Access

Will European Price Control Pressures Affect U.S. Pharmaceutical Pricing?

By Jeremy Spivey, Senior Research Analyst Various European Union countries have put an array of price control tools in place in recent years. For instance, one of the earliest and highest profile is the United Kingdom's National Institute for Health...
 

3.28.2012 Market Access

China’s new “Anhui” pricing model damaging drug quality and product revenue

By Jeremy Spivey, Senior Research Analyst In an effort to expand Chinese citizens' access to certain high-volume pharmaceutical products, the Chinese government has committed to expanding a price-squeezing tendering system to the entire country. The...